Holly M Burke1, Catherine Packer2, Mercy Buluzi3, Elise Healy4, Bagrey Ngwira5. 1. FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA. Electronic address: hburke@fhi360.org. 2. FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA. Electronic address: cpacker@fhi360.org. 3. College of Medicine, University of Malawi, P/Bag 360 Chichiri Blantyre 3, Malawi. Electronic address: buluzim@yahoo.com. 4. FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA. Electronic address: ehealy@fhi360.org. 5. College of Medicine, University of Malawi, P/Bag 360 Chichiri Blantyre 3, Malawi. Electronic address: bagreyngwira@gmail.com.
Abstract
OBJECTIVE: As low- and middle-income countries (LMICs) consider adding self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) to their contraceptive method mix, learning about family planning clients' and providers' experiences with self-injectable DMPA-SC during trials will inform introduction and scale-up efforts. STUDY DESIGN: We conducted semistructured interviews with 30 randomly selected adult women enrolled in the self-administration group of a 12-month randomized controlled trial studying DMPA-SC continuation rates in rural Malawi. We asked about their experiences learning to self-inject, self-injecting, remembering when to reinject, and storing and disposing of DMPA-SC. We also interviewed 12 providers - clinic-based providers (CBPs) and community-based health surveillance assistants (HSAs) - who trained clients to self-inject DMPA-SC during the trial. We asked about their experiences training and supporting women to self-inject DMPA-SC during the trial and their recommendations for scale-up of self-administered DMPA-SC. RESULTS: Clients and providers reported positive experiences with DMPA-SC self-injection. Clients felt that DMPA-SC self-injection saved them time and money, and providers felt that it reduced their workload and saved them time. We found that both CBPs and HSAs successfully trained clients to self-inject DMPA-SC and that clients safely and appropriately stored and disposed of DMPA-SC. CONCLUSIONS: Our findings contribute to the growing body of evidence of the feasibility of DMPA-SC self-injection in LMIC settings. We recommend that providers plan to train clients for at least 30min, emphasize the activating and injecting steps during training, use up to four practice injections per client trained and give self-injectors calendars to help them remember when to reinject. IMPLICATIONS: DMPA-SC self-administration should be made available in LMIC settings, but because it is a new practice, implementation guidance is needed. We offer practical recommendations for introducing and scaling up DMPA-SC self-administration based on clients' and providers' experiences during a trial investigating this practice in Malawi.
RCT Entities:
OBJECTIVE: As low- and middle-income countries (LMICs) consider adding self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) to their contraceptive method mix, learning about family planning clients' and providers' experiences with self-injectable DMPA-SC during trials will inform introduction and scale-up efforts. STUDY DESIGN: We conducted semistructured interviews with 30 randomly selected adult women enrolled in the self-administration group of a 12-month randomized controlled trial studying DMPA-SC continuation rates in rural Malawi. We asked about their experiences learning to self-inject, self-injecting, remembering when to reinject, and storing and disposing of DMPA-SC. We also interviewed 12 providers - clinic-based providers (CBPs) and community-based health surveillance assistants (HSAs) - who trained clients to self-inject DMPA-SC during the trial. We asked about their experiences training and supporting women to self-inject DMPA-SC during the trial and their recommendations for scale-up of self-administered DMPA-SC. RESULTS: Clients and providers reported positive experiences with DMPA-SC self-injection. Clients felt that DMPA-SC self-injection saved them time and money, and providers felt that it reduced their workload and saved them time. We found that both CBPs and HSAs successfully trained clients to self-inject DMPA-SC and that clients safely and appropriately stored and disposed of DMPA-SC. CONCLUSIONS: Our findings contribute to the growing body of evidence of the feasibility of DMPA-SC self-injection in LMIC settings. We recommend that providers plan to train clients for at least 30min, emphasize the activating and injecting steps during training, use up to four practice injections per client trained and give self-injectors calendars to help them remember when to reinject. IMPLICATIONS: DMPA-SC self-administration should be made available in LMIC settings, but because it is a new practice, implementation guidance is needed. We offer practical recommendations for introducing and scaling up DMPA-SC self-administration based on clients' and providers' experiences during a trial investigating this practice in Malawi.
Authors: Rebecca L Callahan; Aurélie Brunie; Victoria Lebrun; Mario Chen; Christine L Godwin; Kanchan Lakhwani; Funmilola M OlaOlorun Journal: Reprod Health Date: 2021-03-22 Impact factor: 3.223
Authors: Caitlin Corneliess; Katelin Gray; Jennifer Kidwell Drake; Allen Namagembe; Aurora Stout; Jane Cover Journal: Sex Reprod Health Matters Date: 2021
Authors: Anne Ammerdorffer; Mark Laws; Manjulaa Narasimhan; Briana Lucido; Agnes Kijo; Lale Say; Arinze Awiligwe; Lester Chinery; A Metin Gülmezoglu Journal: Bull World Health Organ Date: 2022-06-22 Impact factor: 13.831
Authors: Shannon N Wood; Sophia Magalona; Linnea A Zimmerman; Funmilola OlaOlorun; Elizabeth Omoluabi; Pierre Akilimali; Georges Guiella; Peter Gichangi; Philip Anglewicz Journal: BMJ Glob Health Date: 2022-07